Potential biofluid markers and treatment targets for renal cell carcinoma

Nature Reviews Urology

Volumn 10, Issue 6, 2013, Pages 336-344

  Wettersten, Hiromi I ^a   Weiss, Robert H ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPOPHILIN; AQUAPORIN 1; AXITINIB; BEVACIZUMAB; BIOLOGICAL MARKER; CYCLIN D; ENTINOSTAT; ERYTHROPOIETIN; EVEROLIMUS; EXPORTIN 1; HYPOXIA INDUCIBLE FACTOR 1ALPHA; INDOLEAMINE 2,3 DIOXYGENASE; KIDNEY INJURY MOLECULE 1; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; MICRORNA; MICRORNA 378; MICRORNA 451; MYC PROTEIN; PAZOPANIB; PROGRAMMED DEATH 1 RECEPTOR; PROTEIN 14 3 3; QUINOLINIC ACID; SORAFENIB; SUNITINIB; TEMSIROLIMUS; TRYPTOPHAN; UNCLASSIFIED DRUG; VASCULOTROPIN A; VASCULOTROPIN C; VASCULOTROPIN D; VORINOSTAT;

APOPTOSIS; CANCER DIAGNOSIS; CANCER SCREENING; CELL DIFFERENTIATION; CELL PROLIFERATION; EARLY DIAGNOSIS; GENE MUTATION; HUMAN; KIDNEY CARCINOMA; KIDNEY INJURY; LIFE EXPECTANCY; POPULATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION; TRANSITIONAL CELL CARCINOMA; TUMOR MICROENVIRONMENT;

ANIMALS; ANTINEOPLASTIC AGENTS; CARCINOMA, RENAL CELL; DRUG DELIVERY SYSTEMS; HUMANS; KIDNEY NEOPLASMS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 84880273186     PISSN: 17594812     EISSN: 17594820     Source Type: Journal    
DOI: 10.1038/nrurol.2013.52     Document Type: Review

References (137)

1. Ljungberg, B. et al. The epidemiology of renal cell carcinoma. Eur. Urol. 60, 615-621 (2011
2. Eheman, C. et al. Annual Report to the Nation on the status of cancer, 1975-2008, featuring cancers associated with excess weight and lack of sufficient physical activity. Cancer 118, 2338-2366 (2012
3. Hunt, J. D., van der Hel, O. L., McMillan, G. P., Boffetta, P. & Brennan, P. Renal cell carcinoma in relation to cigarette smoking: Meta-analysis of 24 studies. Int. J. Cancer 114, 101-108 (2005
4. Cowey, C. L. & Hutson, T. E. Molecularly targeted agents for renal cell carcinoma: The next generation. Clin. Adv. Hematol. Oncol. 8, 357-364 (2010
5. Ramana, J. RCDB: Renal Cancer Gene Database. BMC Res. Notes 5, 246 (2012
6. Vajdic, C. M. et al. Cancer incidence before and after kidney transplantation. JAMA 296, 2823-2831 (2006
7. Stewart, J. H. et al. The pattern of excess cancer in dialysis and transplantation. Nephrol. Dial. Transplant. 24, 3225-3231 (2009
8. Chow, W. H., Dong, L. M. & Devesa, S. S. Epidemiology and risk factors for kidney cancer. Nat. Rev. Urol. 7, 245-257 (2010
9. Choyke, P. L. Radiologic evaluation of hematuria: guidelines from the American College of Radiology's appropriateness criteria. Am. Fam. Physician 78, 347-352 (2008
10. Muslin, A. J., Tanner, J. W., Allen, P. M. & Shaw, A. S. Interaction of 14-3-3 with signaling proteins is mediated by the recognition of phosphoserine. Cell 84, 889-897 (1996
11. Tzivion, G., Luo, Z. & Avruch, J. A dimeric 14-3-3 protein is an essential cofactor for Raf kinase activity. Nature 394, 88-92 (1998
12. Zha, J., Harada, H., Yang, E., Jockel, J. & Korsmeyer, S. J. Serine phosphorylation of death agonist BAD in response to survival factor results in binding to 14-3-3 not BCL-X(L). Cell 87, 619-628 (1996
13. Zhang, L., Chen, J. & Fu, H. Suppression of apoptosis signal-regulating kinase 1-induced cell death by 14-3-3 proteins. Proc. Natl Acad. Sci. USA 96, 8511-8515 (1999
14. Minamida, S. et al. 14-3-3 protein beta/alpha as a urinary biomarker for renal cell carcinoma: proteomic analysis of cyst fluid. Anal. Bioanal. Chem. 401, 245-252 (2011
15. Liang, S. et al. Quantitative protein expression profiling of 14-3-3 isoforms in human renal carcinoma shows 14-3-3 epsilon is involved in limitedly increasing renal cell proliferation. Electrophoresis 30, 4152-4162 (2009
16. Ichimura, T. et al. Kidney injury molecule-1 (KIM-1), a putative epithelial cell adhesion molecule containing a novel immunoglobulin domain, is up-regulated in renal cells after injury. J. Biol. Chem. 273, 4135-4142 (1998
17. Ichimura, T. Hung, C. C., Yang, S. A., Stevens, J. L. & Bonventre, J. V. Kidney injury molecule-1: A tissue and urinary biomarker for nephrotoxicant-induced renal injury. Am. J. Physiol. 286, F552-F563 (2004
18. Han, W. K. Bailly, V., Abichandani, R., Thadhani, R. & Bonventre, J. V. Kidney Injury Molecule-1 (KIM-1): A novel biomarker for human renal proximal tubule injury. Kidney Int. 62, 237-244 (2002
19. Zhang, Z., Humphreys, B. D. & Bonventre, J. V. Shedding of the urinary biomarker kidney injury molecule-1 (KIM-1) is regulated by MAP kinases and juxtamembrane region. J. Am. Soc. Nephrol. 18, 2704-2714 (2007
20. Han, W. K. et al. Human kidney injury molecule-1 is a tissue and urinary tumor marker of renal cell carcinoma. J. Am. Soc. Nephrol. 16, 1126-1134 (2005
21. Ganti, S. & Weiss, R. H. Urine metabolomics for kidney cancer detection and biomarker discovery. Urol. Oncol. 29, 551-557 (2011
22. Stone, T. W. & Darlington, L. G. Endogenous kynurenines as targets for drug discovery and development. Nat. Rev. Drug Discov. 1, 609-620 (2002
23. Brauch, H. et al. VHL alterations in human clear cell renal cell carcinoma: Association with advanced tumor stage and a novel hot spot mutation. Cancer Res. 60, 1942-1948 (2000
24. Warburg, O. On the origin of cancer cells. Science 123, 309-314 (1956
25. Perroud, B., Ishimaru, T., Borowsky, A. D. & Weiss, R. H. Grade-dependent proteomics characterization of kidney cancer. Mol. Cell. Proteomics 8, 971-985 (2009
26. Popov, A. & Schultze, J. L. IDO-expressing regulatory dendritic cells in cancer and chronic infection. J. Mol. Med. 86, 145-160 (2008
27. Chen, W. IDO: More than an enzyme. Nat. Immunol. 12, 809-811 (2011
28. Godin-Ethier, J. et al. Human activated T lymphocytes modulate IDO expression in tumors through Th1/Th2 balance. J. Immunol. 183, 7752-7760 (2009
29. Morrissey, J. J., London, A. N., Luo, J. & Kharasch, E. D. Urinary biomarkers for the early diagnosis of kidney cancer. Mayo Clin. Proc. 85, 413-421 (2010
30. Huang, Y. et al. Expression of aquaporin 1 in primary renal tumors: A prognostic indicator for clear-cell renal cell carcinoma. Eur. Urol. 56, 690-698 (2009
31. Takenawa, J. et al. Transcript levels of aquaporin 1 and carbonic anhydrase IV as predictive indicators for prognosis of renal cell carcinoma patients after nephrectomy. Int. J. Cancer 79, 1-7 (1998
32. Yao, M. et al. Gene expression analysis of renal carcinoma: Adipose differentiation-related protein as a potential diagnostic and prognostic biomarker for clear-cell renal carcinoma. J. Pathol. 205, 377-387 (2005
33. Yao, M. et al. Expression of adipose differentiation-related protein: A predictor of cancer-specific survival in clear cell renal carcinoma. Clin. Cancer Res. 13, 152-160 (2007
34. Fuhrman, S. A., Lasky, L. C. & Limas, C. Prognostic significance of morphologic parameters in renal cell carcinoma. Am. J. Surg. Pathol. 6, 655-663 (1982
35. Krishnan, B. & Truong, L. D. Renal epithelial neoplasms: The diagnostic implications of electron microscopic study in 55 cases. Hum. Pathol. 33, 68-79 (2002
36. Tun, H. W. et al. Pathway signature and cellular differentiation in clear cell renal cell carcinoma. PLoS ONE 5, e10696 (2010
37. Shukla, G. C., Singh, J. & Barik, S. MicroRNAs: Processing, maturation, target recognition and regulatory functions. Mol. Cell. Pharmacol. 3, 83-92 (2011
38. Gerin, I. et al. Roles for miRNA-378/378* in adipocyte gene expression and lipogenesis. Am. J. Physiol. Endocrinol. Metab. 299, E198-E206 (2010
39. Pulakat, L., Aroor, A. R., Gul, R. & Sowers, J. R. Cardiac insulin resistance and microRNA modulators. Exp. Diabetes Res. 2012, 654904 (2012
40. Lee, D. Y., Deng, Z., Wang, C. H. & Yang, B. B. MicroRNA-378 promotes cell survival, tumor growth, and angiogenesis by targeting SuFu and Fus-1 expression. Proc. Natl Acad. Sci. USA 104, 20350-20355 (2007
41. Mitchell, P. S. et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc. Natl Acad. Sci. USA 105, 10513-10518 (2008
42. Zhu, W., Qin, W., Atasoy, U. & Sauter, E. R. Circulating microRNAs in breast cancer and healthy subjects. BMC Res. Notes 2, 89 (2009
43. Resnick, K. E. et al. The detection of differentially expressed microRNAs from the serum of ovarian cancer patients using a novel real-time PCR platform. Gynecol. Oncol. 112, 55-59 (2009
44. Redova, M. et al. Circulating miR-378 and miR-451 in serum are potential biomarkers for renal cell carcinoma. J. Translat. Med. 10, 55 (2012
45. Godlewski, J. et al. MicroRNA-451 regulates LKB1/AMPK signaling and allows adaptation to metabolic stress in glioma cells. Mol. Cell 37, 620-632 (2010
46. Liu, H. et al. Genome-wide microRNA profiles identify miR-378 as a serum biomarker for early detection of gastric cancer. Cancer Lett. 316, 196-203 (2012
47. Song, J. et al. Identification of suitable reference genes for qPCR analysis of serum microRNA in gastric cancer patients. Dig. Dis. Sci. 57, 897-904 (2012
48. Belldegrun, A. S. et al. Cancer-specific survival outcomes among patients treated during the cytokine era of kidney cancer (1989-2005): A benchmark for emerging targeted cancer therapies. Cancer 113, 2457-2463 (2008
49. Muller, Y. A. et al. Vascular endothelial growth factor: Crystal structure and functional mapping of the kinase domain receptor binding site. Proc. Natl Acad. Sci. USA 94, 7192-7197 (1997
50. Cross, M. J., Dixelius, J., Matsumoto, T. & Claesson-Welsh, L. VEGF-receptor signal transduction. Trends Biochem. Sci. 28, 488-494 (2003
51. Nickerson, M. L. et al. Improved identification of von Hippel-Lindau gene alterations in clear cell renal tumors. Clin. Cancer Res. 14, 4726-4734 (2008
52. Weiss, R. H. & Lin, P. Y. Kidney cancer: Identification of novel targets for therapy. Kidney Int. 69, 224-232 (2006
53. Nicol, D. et al. Vascular endothelial growth factor expression is increased in renal cell carcinoma. J. Urol. 157, 1482-1486 (1997
54. Wilhelm, S. M. et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res. 64, 7099-7109 (2004
55. Huang, D. et al. Sunitinib acts primarily on tumor endothelium rather than tumor cells to inhibit the growth of renal cell carcinoma. Cancer Res. 70, 1053-1062 (2010
56. Presta, L. G. et al. Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res. 57, 4593-4599 (1997
57. Sloan, B. & Scheinfeld, N. S. Pazopanib, a VEGF receptor tyrosine kinase inhibitor for cancer therapy. Curr. Opin. Investig. Drugs 9, 1324-1335 (2008
58. Rini, B. I. et al. Phase 1 dose-escalation trial of tremelimumab plus sunitinib in patients with metastatic renal cell carcinoma. Cancer 117, 758-767 (2011
59. Rini, B. I. et al. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): A randomised phase 3 trial. Lancet 378, 1931-1939 (2011
60. Shackelford, D. B. & Shaw, R. J. The LKB1-AMPK pathway: Metabolism and growth control in tumour suppression. Nat. Rev. Cancer 9, 563-575 (2009
61. Baldewijns, M. M. et al. VHL and HIF signalling in renal cell carcinogenesis. J. Pathol. 221, 125-138 (2010
62. Robb, V. A., Karbowniczek, M., Klein-Szanto, A. J. & Henske, E. P. Activation of the mTOR signaling pathway in renal clear cell carcinoma. J. Urol. 177, 346-352 (2007
63. Herman, J. G. et al. Silencing of the VHL tumor-suppressor gene by DNA methylation in renal carcinoma. Proc. Natl Acad. Sci. USA 91, 9700-9704 (1994
64. Lowinger, T. B., Riedl, B., Dumas, J. & Smith, R. A. Design and discovery of small molecules targeting raf-1 kinase. Curr. Pharmacol. Des. 8, 2269-2278 (2002
65. Mendel, D. B. et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: Determination of a pharmacokinetic/pharmacodynamic relationship. Clin. Cancer Res. 9, 327-337 (2003
66. Solowiej, J. et al. Characterizing the effects of the juxtamembrane domain on vascular endothelial growth factor receptor-2 enzymatic activity, autophosphorylation, and inhibition by axitinib. Biochemistry 48, 7019-7031 (2009
67. Kent, D. et al. Regulation of hematopoietic stem cells by the steel factor/KIT signaling pathway. Clin. Cancer Res. 14, 1926-1930 (2008
68. Dibb, N. J., Dilworth, S. M. & Mol, C. D. Switching on kinases: Oncogenic activation of BRAF and the PDGFR family. Nat. Rev. Cancer 4, 718-727 (2004
69. Gril, B. et al. The B-Raf status of tumor cells may be a significant determinant of both antitumor and anti-angiogenic effects of pazopanib in xenograft tumor models. PLoS ONE 6, e25625 (2011
70. Inoue, H., Hwang, S. H., Wecksler, A. T., Hammock, B. D. & Weiss, R. H. Sorafenib attenuates p21 in kidney cancer cells and augments cell death in combination with DNA-damaging chemotherapy. Cancer Biol. Ther. 12, 827-836 (2011
71. Weiss, R. H. et al. p21 is a prognostic marker for renal cell carcinoma: Implications for novel therapeutic approaches. J. Urol. 177, 63-69 (2007
72. Park, S. H., Park, J. Y. & Weiss, R. H. Antisense attenuation of p21 sensitizes kidney cancer to apoptosis in response to conventional DNA damaging chemotherapy associated with enhancement of phospho-p53. J. Urol. 180, 352-360 (2008
73. Ribas, A. Tumor immunotherapy directed at PD-1. N. Engl. J. Med. 366, 2517-2519 (2012
74. Zhang, J. et al. Renal tubular epithelial expression of the coinhibitory molecule B7-DC (programmed death-1 ligand). J. Nephrol. 19, 429-438 (2006
75. Thompson, R. H. et al. Tumor B7-H1 is associated with poor prognosis in renal cell carcinoma patients with long-term follow-up. Cancer Res. 66, 3381-3385 (2006
76. Thompson, R. H. et al. PD-1 is expressed by tumor-infiltrating immune cells and is associated with poor outcome for patients with renal cell carcinoma. Clin. Cancer Res. 13, 1757-1761 (2007
77. Topalian, S. L. et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N. Engl. J. Med. 366, 2443-2454 (2012
78. Brahmer, J. R. et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N. Engl. J. Med. 366, 2455-2465 (2012
79. Berger, R. et al. Phase I safety and pharmacokinetic study of CT-011, a humanized antibody interacting with PD-1, in patients with advanced hematologic malignancies. Clin. Cancer Res. 14, 3044-3051 (2008
80. Brahmer, J. R. et al. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: Safety, clinical activity, pharmacodynamics, and immunologic correlates. J. Clin. Oncol. 28, 3167-3175 (2010
81. US National Library of Medicine. ClinicalTrials.gov [online], http://clinicaltrials.gov/ct2/show/record/NCT01441765 (2013
82. Chateauvieux, S., Morceau, F., Dicato, M. & Diederich, M. Molecular and therapeutic potential and toxicity of valproic acid. J. Biomed. Biotechnol. doi:10.1155/2010/479364
83. Kuo, M. H. & Allis, C. D. Roles of histone acetyltransferases and deacetylases in gene regulation. Bioessays 20, 615-626 (1998
84. Choudhary, C. et al. Lysine acetylation targets protein complexes and co-regulates major cellular functions. Science 325, 834-840 (2009
85. Harms, K. L. & Chen, X. Histone deacetylase 2 modulates p53 transcriptional activities through regulation of p53-DNA binding activity. Cancer Res. 67, 3145-3152 (2007
86. Duvic, M. & Vu, J. Vorinostat: A new oral histone deacetylase inhibitor approved for cutaneous T-cell lymphoma. Expert Opin. Investig. Drugs 16, 1111-1120 (2007
87. Carew, J. S., Giles, F. J. & Nawrocki, S. T. Histone deacetylase inhibitors: Mechanisms of cell death and promise in combination cancer therapy. Cancer Lett. 269, 7-17 (2008
88. Fritzsche, F. R. et al. Class I histone deacetylases 1, 2 and 3 are highly expressed in renal cell cancer. BMC Cancer 8, 381 (2008
89. Jones, J. et al. The histone deacetylase inhibitor valproic acid alters growth properties of renal cell carcinoma in vitro and in vivo. J. Cell. Mol. Med. 13, 2376-2385 (2009
90. Mahalingam, D. et al. Vorinostat enhances the activity of temsirolimus in renal cell carcinoma through suppression of survivin levels. Clin. Cancer Res. 16, 141-153 (2010
91. Dasari, A. et al. A phase I study of sorafenib and vorinostat in patients with advanced solid tumors with expanded cohorts in renal cell carcinoma and non-small cell lung cancer. Invest. New Drugs 1, 115-125 (2012
92. Shen, L. et al. Class I histone deacetylase inhibitor entinostat suppresses regulatory T cells and enhances immunotherapies in renal and prostate cancer models. PLoS ONE 7, e30815 (2012
93. Whiteside, T. L. Immune suppression in cancer: Effects on immune cells, mechanisms and future therapeutic intervention. Sem. Cancer Biol. 16, 3-15 (2006
94. Turner, J. G. & Sullivan, D. M. CRM1-mediated nuclear export of proteins and drug resistance in cancer. Curr. Med. Chem. 15, 2648-2655 (2008
95. Koyama, M. & Matsuura, Y. An allosteric mechanism to displace nuclear export cargo from CRM1 and RanGTP by RanBP1. EMBO J. 29, 2002-2013 (2010
96. Jung, Y. S., Qian, Y. & Chen, X. Examination of the expanding pathways for the regulation of p21 expression and activity. Cell. Signal. 22, 1003-1012 (2010
97. Noske, A. et al. Expression of the nuclear export protein chromosomal region maintenance/exportin 1/Xpo1 is a prognostic factor in human ovarian cancer. Cancer 112, 1733-1743 (2008
98. van der Watt, P. J. et al. The Karyopherin proteins, Crm1 and Karyopherin beta1, are overexpressed in cervical cancer and are critical for cancer cell survival and proliferation. Int. J. Cancer 124, 1829-1840 (2009
99. Sakakibara, K. et al. CBS9106 is a novel reversible oral CRM1 inhibitor with CRM1 degrading activity. Blood 14, 3922-3931 (2011
100. Shao, C. et al. p53-dependent anticancer effects of leptomycin B on lung adenocarcinoma. Cancer Chemother. Pharmacol. 67, 1369-1380 (2011
101. Turner, J. G., Dawson, J. & Sullivan, D. M. Nuclear export of proteins and drug resistance in cancer. Biochem. Pharmacol. 83, 1021-1032 (2012
102. Turner, J. G., Dawson J. L., Shacham S., Kauffman M. & Sullivan D. M. Novel inhibitors of nuclear export as a treatment for multiple myeloma. Presented at the 2011 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
103. Inoue, H. et al. CRM1 Blockade by Selective Inhibitors of Nuclear Export (SINE) attenuates Kidney Cancer Growth. J. Urol. doi:10.1016/j.juro.2012.10.018
104. Inoue, H., Kauffman, M., Shacham, S., Landesman, Y. & Weiss, R. H. Evaluation of selective inhibitors of nuclear export (SINE) CRM1 inhibitors for the treatment of renal cell carcinoma (RCC). Presented at the 2012 ASCO Annual Meeting
105. US National Library of Medicine. ClinicalTrials.gov [online], http://clinicaltrials.gov/ct2/show/NCT01607892?term=NCT01607892&rank=1 (2012
106. US National Library of Medicine. ClinicalTrials.gov [online], http://clinicaltrials.gov/ct2/show/NCT01607905?term=NCT01607905&rank=1 (2012
107. Semenza, G. L. Evaluation of HIF-1 inhibitors as anticancer agents. Drug Discov. Today 12, 853-859 (2007
108. Klatte, T. et al. Hypoxia-inducible factor 1 alpha in clear cell renal cell carcinoma. Clin. Cancer Res. 13, 7388-7393 (2007
109. Carew, J. S. et al. ELR510444 inhibits tumor growth and angiogenesis by abrogating HIF activity and disrupting microtubules in renal cell carcinoma. PLoS ONE 7, e31120 (2012
110. Issemann, I. & Green, S. Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators. Nature 347, 645-650 (1990
111. Ribet, C. et al. Peroxisome proliferator-activated receptor-alpha control of lipid and glucose metabolism in human white adipocytes. Endocrinology 151, 123-133 (2010
112. Grabacka, M., Plonka, P. M., Urbanska, K. & Reiss, K. Peroxisome proliferator-activated receptor alpha activation decreases metastatic potential of melanoma cells in vitro via down-regulation of Akt. Clin. Cancer Res. 12, 3028-3036 (2006
113. Tachibana, K. et al. Analysis of PPAR alpha function in human kidney cell line using siRNA. Nucleic Acids Symp. Ser. (Oxf.) 50, 257-258 (2006
114. Peters, J. M., Cheung, C. & Gonzalez, F. J. Peroxisome proliferator-activated receptor-alpha and liver cancer: Where do we stand? J. Mol. Med. 83, 774-785 (2005
115. Ganti, S. et al. Kidney tumor biomarkers revealed by simultaneous multiple matrix metabolomics analysis. Cancer Res. 14, 3471-3479 (2012
116. Suchanek, K. M. May, F. J., Lee, W. J., Holman, N. A. & Roberts-Thomson, S. J. Peroxisome proliferator-activated receptor beta expression in human breast epithelial cell lines of tumorigenic and non-tumorigenic origin. Int. J. Cell Biochem. Biol. 34, 1051-1058 (2002
117. Suchanek, K. M. et al. Peroxisome proliferator-activated receptor alpha in the human breast cancer cell lines MCF-7 and MDA-MB-231. Mol. Carcinogen. 34, 165-171 (2002
118. Rini, B. I. Temsirolimus, an inhibitor of mammalian target of rapamycin. Clin. Cancer Res. 14, 1286-1290 (2008
119. Motzer, R. J. et al. Efficacy of everolimus in advanced renal cell carcinoma: A double-blind, randomised, placebo-controlled phase III trial. Lancet 372, 449-456 (2008
120. Angevin, E. et al. Phase I study of dovitinib (TKI258), an oral FGFR, VEGFR, and PDGFR inhibitor, in advanced or metastatic renal cell carcinoma. Clin. Cancer Res. doi:10.1158/1078-0432.CCR-12-2885
121. Yap, T. A. et al. First-in-man clinical trial of the oral pan-AKT inhibitor MK-2206 in patients with advanced solid tumors. J. Clin. Oncol. 29, 4688-4695 (2011
122. Pal, S. K. et al. Novel therapies for metastatic renal cell carcinoma: Efforts to expand beyond the VEGF/mTOR signaling paradigm. Mol. Cancer Ther. 11, 526-537 (2012
123. Dittrich, C. et al. Phase I and pharmacokinetic study of E7070, a chloroindolyl-sulfonamide anticancer agent, administered on a weekly schedule to patients with solid tumors. Clin. Cancer Res. 9, 5195-5204 (2003
124. Underiner, T. L., Herbertz, T. & Miknyoczki, S. J. Discovery of small molecule c-Met inhibitors: Evolution and profiles of clinical candidates. Anticancer Agents Med. Chem. 10, 7-27 (2010
125. US National Library of Medicine. ClinicalTrials.gov [online], http://clinicaltrials.gov/ct2/show/NCT01391130?term=NCT01391130&rank=1 (2012
126. Tolcher, A. W. et al. Phase I study of RO4929097, a gamma secretase inhibitor of Notch signaling, in patients with refractory metastatic or locally advanced solid tumors. J. Clin. Oncol. 30, 2348-2353 (2012
127. Dasari, A. et al. A phase I study of sorafenib and vorinostat in patients with advanced solid tumors with expanded cohorts in renal cell carcinoma and non-small cell lung cancer. Invest. New Drugs 31, 115-125 (2013
128. Tan, J., Cang, S., Ma, Y., Petrillo, R. L. & Liu, D. Novel histone deacetylase inhibitors in clinical trials as anti-cancer agents. J. Hematol. Oncol. 3, 5 (2010
129. Huang, H. et al. A phase II clinical trial of ixabepilone (Ixempra; BMS-247550; NSC 710428), an epothilone B analog, in patients with metastatic renal cell carcinoma. Clin. Cancer Res. 16, 1634-1641 (2010
130. Topalian, S. L. et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N. Engl. J. Med. 26, 2443-2454 (2012
131. Brahmer, J. R. et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N. Engl. J. Med. 26, 2455-2465 (2012
132. US National Library of Medicine. ClinicalTrials.gov [online], http://clinicaltrials.gov/ct2/show/NCT00620594?term=NCT00620594&rank=1 (2012
133. US National Library of Medicine. ClinicalTrials.gov [online], http://clinicaltrials.gov/ct2/show/NCT00854152?term=NCT00854152&rank=1 (2012
134. Kondagunta, G. V. et al. Phase II trial of bortezomib for patients with advanced renal cell carcinoma. J. Clin. Oncol. 22, 3720-3725 (2004
135. US National Library of Medicine. ClinicalTrials.gov [online], http://clinicaltrials.gov/ct2/show/NCT00891280?term=NCT00891280&rank=1 (2011
136. US National Library of Medicine. ClinicalTrials.gov [online], http://clinicaltrials.gov/ct2/show/NCT01609556?term=NCT01609556&rank=1 (2012
137. US National Library of Medicine. ClinicalTrials.gov [online], http://clinicaltrials.gov/ct2/show/NCT00369200?term=NCT00369200&rank=1 (2012